A breakthrough 5-day rapid-remission therapy for treatment-resistant depression. Combines fMRI brain mapping with personalized accelerated theta-burst stimulation (aTBS) to achieve remission in 2.6 days on average.
FDA cleared; expanding deployment across health systems. Commercial momentum growing.
Updated May 2026Checked 10 Oct0 updates this week
fMRI scan identifies the patient's unique depressive neural circuit, determining the optimal brain region for stimulation targeting.
Magnetic coil delivers theta-burst pulses for 10 minutes every hour, 10 times per day for 5 days at personalized intensity.
Algorithms continuously adjust stimulation parameters based on brain response to optimize treatment outcome.
| Spec | SAINT |
|---|---|
| Treatment sessions per day | 10R (reported) |
| Session duration | 10 minutesR (reported) |
| Total treatment duration | 5 daysR (reported) |
| Median time to remission | 2.6 daysR (reported) |
| Remission rate in clinical trials | 79%R (reported) |
R reported by the company
Magnus Medical
SAINT accelerated TMS, depression therapy, precision neuromodulation
Magnus Medical develops SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy), an FDA-cleared 5-day rapid-remission therapy for treatment-resistant depression using precision transcranial magnetic stimulation (TMS). Based on research from Stanford's Brain Stimulation Lab.
